» Articles » PMID: 32642165

A Prognostic 11-DNA Methylation Signature for Lung Squamous Cell Carcinoma

Overview
Journal J Thorac Dis
Specialty Pulmonary Medicine
Date 2020 Jul 10
PMID 32642165
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Lung squamous cell carcinoma (LUSC), as the second frequent subtype of lung cancer, causes lots of mortalities primarily due to a lack of precise prognostic markers and timely treatment intervention. Previous studies have constructed several risk prognostic models based on DNA methylation sites in multiple tumors, whereas, DNA methylation signature of LUSC remains to be built, and its predictive value need to be evaluated.

Methods: The genome-wide DNA methylation data of LUSC samples was obtained from The Cancer Genome Atlas dataset. Univariate Cox analysis and the least absolute shrinkage and selection operator (LASSO) were implemented to identify DNA methylation sites related to overall survival of LUSC patients. Thus, we performed multivariate Cox regression to establish a DNA methylation signature. The Kaplan-Meier (K-M) survival curves and time-dependent receiver operating characteristic (ROC) curves were plotted to estimate the prognostic power of the signature. Comparison with other known prognostic biomarkers, our DNA methylation signature showed higher predictive specificity and sensitivity. In addition, multivariate Cox regression screened out independent prognostic factors and constructed a nomogram.

Results: Several statistical methods were performed to construct an 11-DNA methylation signature. LUSC patients were divided into low- and high-risk group based on risk score, and high-risk group had a shorter survival time. According to the results of K-M and ROC analyses, the 11-DNA methylation signature showed significant sensitivity and specificity in predicting the LUSC patients' overall survival. Finally, we integrated some independent prognostic factors (risk score, metastasis stage, and tobacco smoking history) to construct a nomogram, which has excellent prognostic power and may provide guidance for the therapeutic strategies.

Conclusions: We constructed the first risk prognosis model based on DNA methylation site in LUSC, which showed better predictive ability. In addition, a nomogram integrating the DNA methylation signature, metastasis stage, and tobacco smoking history was developed.

Citing Articles

Integrative pan-cancer analysis reveals a common architecture of dysregulated transcriptional networks characterized by loss of enhancer methylation.

Ankill J, Zhao Z, Tekpli X, Kure E, Kristensen V, Mathelier A PLoS Comput Biol. 2024; 20(11):e1012565.

PMID: 39556603 PMC: 11611269. DOI: 10.1371/journal.pcbi.1012565.


Identification and Validation of Ferroptosis-Related DNA Methylation Signature for Predicting the Prognosis and Guiding the Treatment in Cutaneous Melanoma.

Guo W, Wang X, Wang Y, Zhu S, Zhu R, Zhu L Int J Mol Sci. 2022; 23(24).

PMID: 36555319 PMC: 9778758. DOI: 10.3390/ijms232415677.


Downregulation of T-cell cytotoxic marker IL18R1 promotes cancer proliferation and migration and is associated with dismal prognosis and immunity in lung squamous cell carcinoma.

Guo Q, Wu C, Jiang N, Tong S, Wan J, Xiao X Front Immunol. 2022; 13:986447.

PMID: 36544782 PMC: 9760870. DOI: 10.3389/fimmu.2022.986447.


DNMT3b-mediated SPAG6 promoter hypermethylation affects lung squamous cell carcinoma development through the JAK/STAT pathway.

Wu Q, Yan Y, Shi S, Qi Q, Han J Am J Transl Res. 2022; 14(10):6964-6977.

PMID: 36398260 PMC: 9641444.


A Novel Prognosis Signature Based on Ferroptosis-Related Gene DNA Methylation Data for Lung Squamous Cell Carcinoma.

Wang X, Meng Y, Liu C, Yang H, Zhou S J Oncol. 2022; 2022:9103259.

PMID: 36131791 PMC: 9484906. DOI: 10.1155/2022/9103259.


References
1.
Song J, Wang W, Wang Y, Qin Y, Wang Y, Zhou J . Epithelial-mesenchymal transition markers screened in a cell-based model and validated in lung adenocarcinoma. BMC Cancer. 2019; 19(1):680. PMC: 6624955. DOI: 10.1186/s12885-019-5885-9. View

2.
Croes L, Beyens M, Fransen E, Ibrahim J, Vanden Berghe W, Suls A . Large-scale analysis of methylation reveals its potential as biomarker for breast cancer. Clin Epigenetics. 2018; 10:51. PMC: 5896072. DOI: 10.1186/s13148-018-0479-y. View

3.
Tang R, Chen W, He R, Zeng J, Liang L, Li S . Identification of a RNA-Seq based prognostic signature with five lncRNAs for lung squamous cell carcinoma. Oncotarget. 2017; 8(31):50761-50773. PMC: 5584202. DOI: 10.18632/oncotarget.17098. View

4.
Zhang J, Fu J, Pan Y, Zhang X, Shen L . Silencing of miR-1247 by DNA methylation promoted non-small-cell lung cancer cell invasion and migration by effects of STMN1. Onco Targets Ther. 2016; 9:7297-7307. PMC: 5138046. DOI: 10.2147/OTT.S111291. View

5.
Wu C, Tseng R, Hsu H, Wang Y, Hsu M . Frequent down-regulation of hRAB37 in metastatic tumor by genetic and epigenetic mechanisms in lung cancer. Lung Cancer. 2008; 63(3):360-7. DOI: 10.1016/j.lungcan.2008.06.014. View